Edesa Biotech reported a net loss of $5.4 million ($0.60 per share) for the third quarter ended June 30, 2026, compared to a $1.7 million loss in the prior year period. Operating expenses rose by $3.6 million to $5.5 million, driven primarily by increased R&D costs of $3.1 million to $4.0 million for preparations and manufacturing related to its Phase 2 EB06 vitiligo study. The company completed preparations for this trial and began activating investigational sites in Canada with recruitment expected soon. In its respiratory program, exploratory data showed mortality reductions for paridiprubart in ARDS patients with acute kidney injury. Cash and cash equivalents stood at $10.3 million as of June 30, 2026. Edesa Biotech is a clinical-stage biopharmaceutical company developing host-directed therapeutics for immuno-inflammatory diseases.
